synflorix
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Adverse prevents in premature infants born before 28 + 0 weeks of gestation after vaccation with Synflorix (PhiD-CV) and Infanrix…
Se realizo un ensayo clinico Fase I controlado, aleatorizado y a doble ciegas en ninos de 4-5 anos de edad, en el Hospital…
An Argentinean court has dismissed an appeal by the drug company GlaxoSmithKline (GSK) and upheld a fine of 400 000 pesos (£61…
Last year several scientific organizations collaborated in drafting the guidelines for prevention of infections after…
Several vaccines against Streptococcus pneumoniae are available. One made of capsular polysaccharides with 23 antigens and the…
.................................................................................................................................................... 7 Þakkir ........................................................................................................................................................ 9 Efnisyfirlit ................................................................................................................................................10 Myndaskrá ..............................................................................................................................................13 Töfluskrá .................................................................................................................................................14 Listi yfir skammstafanir ...........................................................................................................................15 1 Inngangur........................................................................................................................................16 1.1 Kynning á Streptococcus pneumoniae .................................................................................. 16 1.2 Pneumókokkasýklun og pneumókokkasýkingar.................................................................... 16 1.2.1 Heimkynni og smitleiðir .............................................................................................. 16 1.2.2 Samspil meinvirkniþátta pneumókokka og hýsilfrumna við sýklun............................ 17 1.2.3 Pneumókokkasýklun meðal heilbrigðra barna........................................................... 18 1.2.4 Pneumókokkasýkingar .............................................................................................. 19 1.3 Bóluefni .................................................................................................................................. 22 1.3.1 Saga þróunar pneumókokkabóluefna ....................................................................... 22 1.3.2 Fjölsykrubóluefni gegn 23 hjúpgerðum pneumókokka (PPV23) ............................... 23 1.3.3 Próteintengt bóluefni gegn 7 hjúpgerðum pneumókokka (Prevnar) .......................... 23 1.3.4 Próteintengt bóluefni gegn 13 hjúpgerðum pneumókokka (Prevnar13) .................... 24 1.3.5 Próteintengt bóluefni gegn 10 hjúpgerðum pneumókokka (Synflorix) ...................... 24 1.3.6 Áhrif bólusetninga á sýklun, tíðni sýkinga og dreifingu hjúpgerða ............................ 25 1.3.7 Þróun nýrra bóluefna ................................................................................................. 27 1.4 Meinvirkniþættir pneumókokka .............................................................................................. 28 1.4.1 Fjölsykruhjúpurinn – bygging og nafngift ................................................................... 28 1.4.2 Tjáning og myndun fjölsykruhjúpsins ........................................................................ 28 1.4.3 Fjölsykruhjúpurinn sem meinvirkniþáttur ................................................................... 30 1.4.4 Hjúpskipti ................................................................................................................... 33 1.4.5 Aðrir meinvirkniþættir pneumókokka ......................................................................... 34 1.5 Greining og hjúpgreining pneumókokka ................................................................................ 36 1.5.1 Greining pneumókokka .............................................................................................. 36 1.5.2 Tilgangur og aðferðafræði hjúpgreininga .................................................................. 36 1.5.3 Ónæmisfræðilegar hjúpgreiningaraðferðir ................................................................. 37 1.5.4 Hjúpgreining með kjarnsýrumögnun (PCR) ............................................................... 38 2 Markmið ..........................................................................................................................................42 3 Efni og aðferðir ...............................................................................................................................43
Synflorix™ (10-valent pneumococcal conjugate vaccine; GlaxoSmithKline Biologicals, Belgium) has been investigated globally to…
This review provides information on the two vaccines that have become more widely used in singapore children in the recent year…
OBJECTIVE
Review of articles on efficacy and safety of co-administration of Neisseria meningitidis serogroup C -tetanus toxoid…